Entera Bio to Report Second Quarter 2020 Business and Financial Results on August 20, 2020
August 17 2020 - 8:30AM
Entera Bio Ltd. (NASDAQ: ENTX), a leader in the development of
orally delivered large molecule therapeutics, announced it will
report business and financial results for the quarter ended June
30, 2020 on August 20, 2020, before the U.S. financial markets
open.
Entera’s management will host a conference call
on Thursday, August 20, 2020 at 8:30 a.m. EDT to discuss the
results for the quarter. A question-and-answer session will follow
Entera’s remarks. To participate on the live call, please dial
(855) 547-3865 (US) or (409) 217-8787 (international) and provide
the conference ID “5243229” five to ten minutes before the start of
the call.
To access a live audio webcast of the
presentation on the “Investor Relations” page of Entera’s website,
please click here. A replay of the webcast will be archived on
Entera’s website for approximately 45 days following the
presentation.
About Entera Bio
Entera is a leader in the development of orally
delivered macromolecule therapeutics for use in areas with
significant unmet medical need where adoption of injectable
therapies is limited due to cost, convenience and compliance
challenges for patients. The Company’s proprietary, oral drug
delivery technology is designed to address the technical challenges
of poor absorption, high variability, and the inability to deliver
large molecules to the targeted location in the body through the
use of a synthetic absorption enhancer to facilitate the absorption
of large molecules, and protease inhibitors to prevent enzymatic
degradation and support delivery to targeted tissues. The Company’s
most advanced product candidates, EB613 for the treatment of
osteoporosis and EB612 for the treatment of hypoparathyroidism are
in Phase 2 clinical development. Entera also licenses its
technology to biopharmaceutical companies for use with their
proprietary compounds and, to date, has established a collaboration
with Amgen Inc. For more information on Entera Bio, visit
www.enterabio.com.
Contact:
Jonathan Lieber, CFO
Tel: +001 617-362-3579
jon@enterabio.com
Entera Bio (NASDAQ:ENTX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Entera Bio (NASDAQ:ENTX)
Historical Stock Chart
From Apr 2023 to Apr 2024